Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress
Company Announces Appointment of Roger Sawhney, M.D. as a New Member of the Board of DirectorsSINGAPORE and NORTH BRUNSWICK, N.J....
Clinical Trial
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC...
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage...
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q’25 Strong financial position...
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet...
Evaxion to Present One-Year Clinical Efficacy Data from its Phase 2 Study on Lead Cancer Vaccine Candidate, EVX-01, at the ESMO Congress 2024 in September
COPENHAGEN, Denmark, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in...
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN)Presented data from Phase 2b ORIGIN study at ERA24 Congress...
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before...
KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA*...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August...
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients- Dermata continues...
Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report
JERSEY CITY, N.J. , Aug. 7, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report...
DCN Dx to Showcase New Technologies at NextGen Dx 2024
Discover the Advanced miniDxR Customizable Lateral Flow Reader and Comprehensive CDMO and CRO Services at Booth 30 CARLSBAD, Calif, Aug....
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during...
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baselineCNM-Au8 treated...
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET)2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total...
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
CarnoSyn® Brands Unveils TriBsyn™ – “The World’s First Paresthesia-Free Beta-Alanine Powder”
CARLSBAD, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Exclusively from Natural Alternatives International, Inc. (NAI), CarnoSyn® Brands portfolio of patented...